US FDA approves Apellis’ geographic atrophy therapy Syfovre
Pharmaceutical Technology
FEBRUARY 20, 2023
The US Food and Drug Administration (FDA) has granted approval for Apellis Pharmaceuticals’ Syfovre (pegcetacoplan injection) to treat geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The post US FDA approves Apellis’ geographic atrophy therapy Syfovre appeared first on Pharmaceutical Technology.
Let's personalize your content